logicbio
therapeutics
receives
fda
fast
track
designation
treatment
methylmalonic
acidemia
mma
lexington
globe
newswire
logicbio
therapeutics
nasdaq
logc
logicbio
company
dedicated
extending
reach
genetic
medicine
pioneering
targeted
delivery
platforms
announced
today
food
drug
administration
fda
granted
fast
track
designation
clinical
candidate
treatment
methylmalonic
acidemia
mma
according
fda
purpose
fast
track
designation
get
important
new
drugs
patients
earlier
facilitating
development
expediting
review
drugs
treat
serious
conditions
fill
unmet
medical
need
commenting
announcement
daniel
gruskin
senior
vice
president
head
clinical
development
logicbio
said
pleased
fda
granted
fast
track
designation
recognition
importance
efforts
bring
durable
treatment
children
suffering
mma
fast
track
status
plan
continue
work
closely
fda
fully
utilize
opportunities
presented
designation
make
available
patients
quickly
fast
track
designation
fda
fast
track
designation
process
designed
expedite
facilitate
review
product
candidates
treat
serious
conditions
fill
unmet
medical
need
fast
track
designation
allows
early
frequent
communication
fda
throughout
entire
drug
development
review
process
may
also
allow
priority
rolling
review
company
biologics
license
application
bla
logicbio
therapeutics
logicbio
therapeutics
dedicated
extending
reach
genetic
medicine
pioneering
targeted
delivery
platforms
logicbio
proprietary
genome
editing
technology
platform
generide
enables
integration
therapeutic
transgene
without
nucleases
exogenous
promoters
harnessing
native
process
homologous
recombination
logicbio
received
fda
clearance
clinical
trial
wholly
owned
genome
editing
program
leveraging
generide
treatment
methylmalonic
acidemia
patient
enrollment
expected
begin
early
addition
logicbio
collaboration
takeda
research
develop
investigational
therapy
leveraging
generide
treatment
rare
pediatric
disease
syndrome
logicbio
also
developing
next
generation
capsid
platform
use
gene
editing
gene
therapies
data
presented
shown
capsids
deliver
highly
efficient
functional
transduction
human
hepatocytes
improved
manufacturability
low
levels
neutralizing
antibodies
human
samples
capsid
candidates
effort
demonstrated
significant
improvements
benchmark
aavs
currently
clinical
development
logicbio
developing
highly
potent
vectors
internal
development
candidates
potentially
business
development
collaborations
logicbio
headquartered
lexington
mass
information
please
visit
forward
looking
statements
press
release
contains
statements
within
meaning
federal
securities
laws
including
related
timing
progress
results
company
research
development
activities
including
related
significance
benefits
receiving
fda
fast
track
designation
mma
statements
historical
facts
based
management
beliefs
assumptions
information
currently
available
subject
risks
uncertainties
could
cause
actual
results
implementation
company
plans
vary
materially
including
risks
associated
initiation
cost
timing
progress
results
company
current
future
research
development
activities
preclinical
studies
potential
future
clinical
trials
particular
impact
pandemic
company
ability
progress
research
development
manufacturing
regulatory
efforts
including
company
plans
initiate
advance
complete
phase
clinical
trial
mma
value
market
company
common
stock
depend
future
developments
highly
uncertain
predicted
confidence
time
ultimate
duration
pandemic
travel
restrictions
quarantines
social
distancing
business
closure
requirements
united
states
countries
effectiveness
actions
taken
globally
contain
treat
disease
risks
discussed
company
filings
securities
exchange
commission
sec
including
without
limitation
company
annual
report
form
filed
march
sec
company
quarterly
report
form
filed
may
company
subsequent
quarterly
reports
form
filings
sec
except
required
law
company
assumes
obligation
update
statements
publicly
even
new
information
becomes
available
future
contact
matthias
jaffe
chief
financial
officer
mjaffe
